Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Positron Emission Tomography · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Positron Emission Tomography | PROCEDURE | - |
Inclusion Criteria: * Male or female. (If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative serum or urine pregnancy test is required.) * Known or suspected primary or metastatic tumours of myeloma, sarcoma, testicular carcinoma (semi...
Top 20 of 30 competitors
Positron Emission Tomography is an investigational imaging approach being studied for use in sarcoma and other low-incidence cancers. It was evaluated in a Phase 2 clinical trial in Canada with 1,075 participants. The study was completed, and the agent remains in clinical development.
Avalon GloboCare Corp. (NASDAQ: ALBT) is developing Positron Emission Tomography. The company conducted a Phase 2 clinical trial of the imaging agent in patients with known or suspected cancers of low incidence, including sarcoma.
Positron Emission Tomography is in Phase 2 clinical development. A Phase 2 study, NCT00123773, has been completed. The trial was uncontrolled and not blinded, and it enrolled 1,075 participants with sarcoma and other low-incidence cancers.
Positron Emission Tomography has one completed clinical trial, NCT00123773, titled 'Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence.' The Phase 2 study enrolled 1,075 participants in Canada and included conditions such as sarcoma, multiple myeloma, and testicular, ovarian, and kidney neoplasms.
Positron Emission Tomography is not FDA approved. It is an investigational imaging agent that has completed a Phase 2 clinical trial, NCT00123773, in patients with low-incidence cancers including sarcoma. The agent remains in clinical development and has not been approved for any use.